RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

Launched by UNIVERSITY OF FLORENCE · May 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called rimegepant to see how well it works as a preventive treatment for people who suffer from migraines. The trial includes individuals who experience different types of migraines, including those with and without aura (a warning sign like visual disturbances), as well as chronic migraines, which occur frequently. Researchers are looking for participants who have at least four migraine days each month and have kept a headache diary for at least the previous months.

If you are interested in participating, you should be between 18 and 65 years old and meet specific criteria related to your migraine diagnosis. However, if you have certain health conditions or are pregnant or breastfeeding, you may not be eligible. Throughout the trial, participants will receive rimegepant and will be monitored for how well they tolerate the medication and its effectiveness in reducing migraine frequency. This could be a great opportunity to contribute to migraine research while potentially finding relief from your symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III);
• • At least 4 monthly migraine days;
• • Good compliance to study procedures;
• • Availability of headache diary at least of the preceding months before enrollment.
• Exclusion Criteria:
• • Subjects with contraindications for use of gepants;
• • Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
• • medical comorbidities that could interfere with study results;
• • Pregnancy and breastfeeding.
• • Changes in preventive treatments in the month before the first administration of rimegepant